Certainly, it should be mentioned that in the case of an EGFR-mutant NSCLC with secondary resistance to EGFR TKI therapy, NTRK testing should be always considered as NTRK1 fusions have been described as an escape mechanism against EGFR TKI therapy [35]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.